Stock events for Inhibikase Therapeutics, Inc. (IKT)
Inhibikase Therapeutics, Inc. stock price has been impacted by several key events in the past six months. The company's stock experienced a significant drop in January 2025 after announcing the pausing of further development of its Parkinson's disease drug. In October 2025, Inhibikase raised $110 million through a private placement to advance its pulmonary arterial hypertension candidate. In November 2025, Inhibikase announced its expectation to advance IKT-001 into a global pivotal Phase 3 clinical study for PAH. The company saw price target decreases from analysts in December 2025. B of A Securities initiated coverage of Inhibikase Therapeutics with a "Buy" recommendation in January 2026. The stock jumped in February 2026 due to positive sentiment around promising FDA designations, but the stock price has been volatile. Over the past year, IKT's shares have hit a 52-week high of $2.58 and a 52-week low of $1.33 and has underperformed both the US Biotechs industry and the broader US market.
Demand Seasonality affecting Inhibikase Therapeutics, Inc.’s stock price
As a clinical-stage pharmaceutical company, Inhibikase Therapeutics, Inc. is primarily engaged in the research and development of drug candidates, and there is no discernible demand seasonality for its products and services at this time.
Overview of Inhibikase Therapeutics, Inc.’s business
Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing protein kinase inhibitor therapeutics within the Biotechnology industry. The company is dedicated to modifying the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its major product candidates include IkT-148009 (Risvodetinib), an Abelson Tyrosine Kinase inhibitor, and IkT-001Pro, a prodrug of imatinib mesylate.
IKT’s Geographic footprint
Inhibikase Therapeutics, Inc. is headquartered in Atlanta, Georgia, with a legal address in Wilmington, Delaware, United States. The company has research and development collaborations with several institutions within the United States and an international partnership with the University of Bordeaux.
IKT Corporate Image Assessment
Inhibikase Therapeutics' brand reputation has been shaped by both positive developments and setbacks in the past year. The company has received a consensus "Buy" rating from analysts, with some firms issuing "Strong Buy" recommendations. Positive events include FDA Designations and Trial Progress for IkT-001Pro and Analyst Coverage. Challenges include Disappointing Phase II Results for Risvodetinib and Financial Instability.
Ownership
Inhibikase Therapeutics, Inc. has a significant number of institutional owners and shareholders. As of March 3, 2026, there were 90 institutional owners holding a total of 104,805,581 shares. Individual investors possess the maximum shares in the company, holding a 39% stake, while institutional ownership stands at 30%. The top 11 shareholders control 51% of the business. Major institutional owners include Sands Capital Ventures, LLC, Soleus Capital Management, L.P., Fairmount Funds Management LLC, and others.
